Alpha Tau Medical Ltd Total Assets
Alpha Tau Medical Ltd total assets. Based on the latest financial reports, Alpha Tau Medical Ltd (DRTS) holds total assets worth $104.69 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Alpha Tau Medical Ltd (DRTS) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Alpha Tau Medical Ltd (2019–2024)
Total assets of Alpha Tau Medical Ltd from 2019 to 2024. This chart illustrates how Alpha Tau Medical Ltd's total assets have evolved over time, based on quarterly financial data. See Alpha Tau Medical Ltd (DRTS) stock price for real-time trading data and today's change.
Alpha Tau Medical Ltd - Asset Composition Analysis
Alpha Tau Medical Ltd Total Assets Breakdown (December 2024)
Alpha Tau Medical Ltd total assets breakdown as of December 2024. Alpha Tau Medical Ltd's total assets of $104.69 Million consist of 74.5% current assets and 25.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 15.9% |
| Accounts Receivable | $332.00K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Alpha Tau Medical Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore DRTS working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alpha Tau Medical Ltd's current assets represent 74.5% of total assets in 2024, a decrease from 94.5% in 2019.
- Cash Position: Cash and equivalents constituted 15.9% of total assets in 2024, up from 5.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
Alpha Tau Medical Ltd Competitors by Total Assets
Key competitors of Alpha Tau Medical Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Alpha Tau Medical Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.43 | 10.99 | 22.73 |
| Quick Ratio | 8.43 | 10.99 | 22.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $67.96 Million | $63.44 Million | $45.37 Million |
Alpha Tau Medical Ltd - Advanced Valuation Insights
This section examines the relationship between Alpha Tau Medical Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.92 |
| Latest Market Cap to Assets Ratio | 7.13 |
| Asset Growth Rate (YoY) | -19.7% |
| Total Assets | $86.20 Million |
| Market Capitalization | $614.75 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Alpha Tau Medical Ltd's assets at a significant premium (7.13x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Alpha Tau Medical Ltd's assets decreased by 19.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Alpha Tau Medical Ltd (2019–2024)
The table below shows the annual total assets of Alpha Tau Medical Ltd from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $86.20 Million | -19.73% |
| 2023-12-31 | $107.39 Million | -10.62% |
| 2022-12-31 | $120.15 Million | +184.61% |
| 2021-12-31 | $42.22 Million | -20.33% |
| 2020-12-31 | $52.99 Million | +67.92% |
| 2019-12-31 | $31.56 Million | -- |
About Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending cl… Read more